@article {PINILLA-IBARZ6355, author = {JAVIER PINILLA-IBARZ and KENDRA SWEET and JOSEPHINE EMOLE and MICHAEL FRADLEY}, title = {Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia}, volume = {35}, number = {12}, pages = {6355--6364}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {With the success of tyrosine kinase inhibitor (TKI) therapy for the treatment of patients with chronic myeloid leukemia (CML), CML is now treated as a chronic disease. As such, the community of oncologists may see patients with CML more often than the primary-care physician and must focus on long-term management of adverse events and adherence. BCR-ABL1 TKIs are effective therapies in CML but are associated with distinct safety profiles. Thus, selection of long-term treatment with any TKI requires assessment of patient comorbidities and regular monitoring to identify the potential emergence of adverse effects or new risk factors. With a focus on long-term safety, this review provides a holistic picture of the primary care needs of patients with CML, emphasizing on the importance of community oncologists who in many cases act as both oncologists and primary-care physicians.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/12/6355}, eprint = {https://ar.iiarjournals.org/content/35/12/6355.full.pdf}, journal = {Anticancer Research} }